Pulmonary emphyzema: Mechanisms and therapeutic perspectives;Emphysème pulmonaire: Mécanismes et nouvelles perspectives thérapeutiques

Revue Medicale Suisse

Volumn 1, Issue 41, 2005, Pages 2664-2672

  Egger, Bernard ^a   Aubert, John David ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CIGARETTE SMOKE; CYSTEINE PROTEINASE INHIBITOR; MATRIX METALLOPROTEINASE; PROTEINASE; SERINE PROTEINASE INHIBITOR;

ARTICLE; EMPHYSEMA; HUMAN; LUNG EMPHYSEMA; LYMPHOCYTE; MACROPHAGE; NEUTROPHIL; OXIDATIVE STRESS; PATHOGENESIS; REVIEW;

HUMANS; PULMONARY EMPHYSEMA;

EID: 33644941592     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001;163:1256-76.
2. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-46.
3. Screaton NJ KT. Emphysema and smoking-related lung diseases. Imaging 2004;16:50-60.
4. Turato G, Zuin R, Miniati M, et al. Airway inflammation in severe chronic obstructive pulmonary disease: Relationship with lung function and radiologic emphysema. Am J Respir Crit Care Med 2002;166:105-10.
5. Sutherland ER, Martin RJ. Airway inflammation in chronic obstructive pulmonary disease: Comparisons with asthma. J Allergy Clin Immunol 2003;111:819-27; quiz 28.
6. Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med 1997;156: 341-57.
7. Suki B, Lutchen KR, Ingenito EP. On the progressive nature of emphysema : Roles of proteases, inflammation, and mechanical forces. Am J Respir Crit Care Med 2003; 168:516-21.
8. Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 2004;56:515-48.
9. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: Molecular and cellular mechanisms. Eur Respir J 2003;22:672-88.
10. Shapiro SD, Goldstein NM, Houghton AM, Kobayashi DK, Kelley D, Belaaouaj A. Neutrophil elastase contributes to cigarette smoke-induced emphysema in mice. Am J Pathol 2003;163:2329-35.
11. Shapiro SD, Senior RM. Matrix metalloproteinases. Matrix degradation and more. Am J Respir Cell Mol Biol 1999;20:1100-2.
12. DeMeo DL, Silverman EK. Alpha1-antitrypsin deficiency. 2: Genetic aspects of alpha(1)-antitrypsin deficiency: Phenotypes and genetic modifiers of emphysema risk. Thorax 2004;59:259-64.
13. Carrell RW, Lomas DA. Alpha1-antitrypsin deficiency - a model for conformational diseases. N Engl J Med 2002;346:45-53.
14. Dahl M, Hersh CP, Ly NP, Berkey CS, Silverman EK, Nordestgaard BG. The protease inhibitor PI*S allele and COPD: A meta-anarysis. Eur Respir J 2005;26:67-76.
15. Gadek JE, Pacht ER. Pathogenesis of hereditary emphysema and replacement therapy for alpha 1-antitrypsin deficiency. Insight into the more common forms of emphysema. Chest 1996;110(6 Suppl.):248S-50S.
16. Tuder RM, Zhen L, Cho CY, et al. Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade. Am J Respir Cell Mol Biol 2003;29:88-97.
17. Licker M. Chirurgie de réduction de volume pulmonaire. Ann Fr Anesth Réanim 1999;18:196-210.
18. Fein AM, Branman SS, Casaburi R, et al. Lung volume reduction surgery. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, May 1996. Am J Respir Crit Care Med 1996; 154:1151-2.
19. Maurer JR, Frost AE, Estenne M, Higenbottam T, Glanville AR. International guidelines for the selection of lung transplant candidates. The International Society for Heart and Lung Transplantation, the American Thoracic Society, the American Society of Transplant Physicians, the European Respiratory Society. Transplantation 1998; 66:951-6.
20. Arcasoy SM, Kotloff RM. Lung transplantation. N Engl J Med 1999;340:1081-91.
21. Wewers MD, Casolaro MA, Sellers SE, et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med 1987;316:1055-62.
22. Wencker M, Fuhrmann B, Banik N, Konietzko N. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Chest 2001;119:737-44.
23. Sandhaus RA. alpha 1-Antitrypsin deficiency. 6: New and emerging treatments for alpha 1-antitrypsin deficiency. Thorax 2004;59:904-9.
24. Barnes PJ. Chronic obstructive pulmonary disease * 12: New treatments for COPD. Thorax 2003;58:803-8.
25. Rubio ML, Martin-Mosquero MC, Ortega M, Peces-Barba G, Gonzalez-Mangado N. Oral N-acetylcysteine attenuates elastase-induced pulmonary emphysema in rats. Chest 2004;125:1500-6.
26. Grandjean EM, Berthet P, Ruffmann R, Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: A meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther 2000;22:209-21.
27. Lundbäck B, et al. Possible effect of acetylcysteine on lung function. Eur Respir J 1995;5(Suppl.):895.
28. Decramer M, Rutten-van Molken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): A randomised placebo-controlled trial. Lancet 2005;365:1552-60.
29. Massaro GD, Massaro D. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat Med 1997;3:675-7.
30. Barnes PJ, Hansel TT. Prospects for new drugs for chronic obstructive pulmonary disease. Lancet 2004;364: 985-96.
31. Mao JT, Goldin JG, Dermand J, et al. A pilot study of all-trans-retinoic acid for the treatment of human emphysema. Am J Respir Crit Care Med 2002;165:718-23.